ARROWHEAD PHARMACEUT

ARWR
Delayed Quote. Delayed  - 01/22 04:00:00 pm
82.07USD +2.56%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: September 2020 2021
Net sales1 88,0198
EBITDA1 -87,2-76,0
Operating profit (EBIT)1 -93,2-41,8
Operating Margin -106%-21,1%
Pre-Tax Profit (EBT)1 -84,6-8,44
Net income1 -84,6-8,44
Net margin -96,1%-4,26%
EPS2 -0,84-0,24
Dividend per Share2 --
Last update 11/23/202012/16/2020
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: September 2020 2021
Net Debt1 --
Net Cash position1 315286
Leverage (Debt / EBITDA) 3,62x3,77x
Free Cash Flow1 -10737,4
ROE (Net Profit / Equities) -13,0%
Shareholders' equity1 --64,9
ROA (Net Profit / Asset) --
Assets1 --
Book Value Per Share2 -5,61
Cash Flow per Share --
Capex1 12,011,1
Capex / Sales 13,6%5,60%
Last update 11/23/202001/12/2021
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 8 433 M $ -
Entreprise Value (EV) 8 147 M $ 8 239 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) -335x -119x
Capitalization / Revenue 42,5x 48,2x
EV / Revenue 41,1x 46,5x
EV / EBITDA -107x -62,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 14,6x 18,6x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -21,1% -43,6%
Operating Leverage (Delta EBIT / Delta Sales) 0,44x -7,02x
Net Margin (Net Profit / Revenue) -4,26% -30,0%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) 13,0% -32,4%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   5,60% 6,13%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend